GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.
EPIDIOLEX significantly reduced difficult-to-treat seizures, both focal and generalized — GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that JAMA Neurology has published results of the company’s positive Phase 3 clinical trial of […]
– Meeting Highlights Include New Long-Term Data in Tuberous Sclerosis Complex – CARLSBAD, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that a variety of data, including long-term data in the treatment of tuberous sclerosis […]
– Results from analysis of three Phase 3 clinical studies showed statistically significant improvement in spasticity in people with multiple sclerosis – Treatment with nabiximols seen in this analysis was not associated with increased muscle weakness or a notable change in preferred walking speed CARLSBAD, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — Greenwich Biosciences, U.S. subsidiary of […]